Nuclear Medicine and Molecular Imaging

  • 제41권3호
  • /
  • Pages.247-251
  • /
  • 2007
  • /
  • 1869-3474(pISSN)
  • /
  • 1869-3482(eISSN)
대한핵의학회 (The Korean Society of Nuclear Medicine)
권호 표지

I-131 MIBG와 F-18 FDG 섭취의 불일치를 보였던 악성 부신경절종 1례

A Significant Discrepancy of Uptake between I-131 MIBG and F-18 FDG in a Patient With Malignant Paraganglioma

  • Kim, Jong-Su (Department of Internal Medicine, National Police Hospital) ;
  • Kim, Hyun-Keun (Department of Internal Medicine, National Police Hospital) ;
  • Choi, Kyu-Young (Department of Internal Medicine, National Police Hospital) ;
  • Park, Hyung-Ki (Department of Internal Medicine, National Police Hospital) ;
  • Kim, Eun-Sil (Department of Internal Medicine, National Police Hospital) ;
  • Kim, Yun-Kwon (Department of Internal Medicine, National Police Hospital) ;
  • Kim, So-Yon (Department of Internal Medicine, National Police Hospital) ;
  • Kim, Young-Jung (Department of Internal Medicine, National Police Hospital) ;
  • Lee, Hyo-Jin
  • 발행 : 2007.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

A 38-year-old man who was diagnosed with malignant paraganglioma underwent computed tomography (CT) and I-131 metaiodobenzylguanidine (MIBG) san. CT showed extensive lymph node enlargement in right iliac area and retroperitoneum with severe hydronephrosis and mass on posterior bladder wall. However, I-131 MIBG scan didn't showed abnormal uptake. He also underwent F-18 fluorodeoxyglucose (FDG) positron emisson tomography/CT for localizing accurate tumor site. F-18 FDG PET/CT showed multiple metastases of left supraclavicular, hilar, mediastinal para-aortic, inguinal, right iliac lymph nodes, lung, vertebrae, and pelvis. There are a few reports showing that the F-18 FDG PET/CT is helpful for staging and localizing tumor site of patients who are diagnosed with negative on the MIBG scans. Thus, we report a case with paraganglioma which showed negative I-131 MIBG scan, but revealed multiple intense hypermetabolic foci in F-18 FDG PET/CT.

키워드

참고문헌

  1. Plouin PF, Gimenez-Roqueplo AP. Initial work-up and long-term follow-up in patients with phaeochromocytomas and paragangliomas. Best Practice & Research Clinical Endocrinology & Metabolism 2006;20:421-34 https://doi.org/10.1016/j.beem.2006.07.004
  2. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005;366:665-75 https://doi.org/10.1016/S0140-6736(05)67139-5
  3. Tischler, A. The adrenal medulla and extra-adrenal paraganglia. In: Kovacs K, Asa S, eds. Functional Endocrine pathology Oxford: Blackwell 1998. p. 550-95
  4. Ilias I, Pacak K. Current Approaches and Recommended Algorithm for the Diagnostic Localization of Pheochromocytoma. J Clin Endocrinol Metab 2004;89:479-91 https://doi.org/10.1210/jc.2003-031091
  5. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetics, diagnosis, localization and treatment of pheochromocytoma. ann Int Med 2001;134:315-29 https://doi.org/10.7326/0003-4819-134-4-200102200-00016
  6. Quint LE, Glazer GM, Francis IR, Shapiro B, Chenevert TL. Pheochromocytoma and paraganglioma: comparision of MR imaging with CT and I-131 MIBG scintigraphy. Radiology 1987;165:89-93 https://doi.org/10.1148/radiology.165.1.3628794
  7. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: Imaging with 2-[fluorine-18]fluoro-2-deoxy-Dglucose PET. Radiology 1999;212:35-41 https://doi.org/10.1148/radiology.212.1.r99jl3035
  8. Ezuddin S, Fragkaki C. MIBG and FDG PET findings in a patient with malignant pheochromocytoma : a significant discrepancy. Clin Nucl Med 2005;30:579-81 https://doi.org/10.1097/01.rlu.0000170060.52675.14
  9. Goldfarb CR, Srivastava NC, Grotas AB, Onqseng F, Nagler HM. Radionuclide imaging in urology. Urol Clin North Am 2006;33: 319-28 https://doi.org/10.1016/j.ucl.2006.03.006
  10. Sood R, Story A, Rossleigh MA, Haindle W, Guille J, Pillai D. Superiority of F-18 FDG PET Imaging for Detection of a Pheochromocytoma. Clinical Nuclear Medicine 2006;31:13-5 https://doi.org/10.1097/01.rlu.0000191349.47208.2a
  11. Berglund AS, Hulthen UL, Manhem P, Thorsson O, Wollmer P, Tornquist C. Metaiodobenzylguanidine (MIBG) scintigraphy and computed tomography (CT) in clinical practice. Primary and secondary evaluation for localization of phaeochromocytomas. J Intern Med 2001;249:247-51 https://doi.org/10.1046/j.1365-2796.2001.00792.x
  12. Maurea S, Cuocolo A, Reynolds JC, Tumeh SS, Begley MG, Linehan WM, et al. Iodine-131-metaiodobenzylguanidine scintigraphy in preoperatie and postoperative evaluation of paragangliomas : comparison with CT and MRI. J Nucl Med 1993;34: 173-9
  13. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta- iodobenzylguanidine (MIBG). Nucl Med Commun 1992;13:513- 21 https://doi.org/10.1097/00006231-199207000-00006
  14. 고창순. 핵의학. 2판: 고려의학; 1997. p. 737
  15. van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, et al. [$^{123}$]Metaiodobenzylguanidine and [$^{111}$In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001;86:685-93 https://doi.org/10.1210/jc.86.2.685
  16. Mamede M, Carrasquillo J, Chen CC, Del corral P, Whatley M, Ilias I. Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [(123)I]-metaiodobenzylguanidinenegative metastatic pheochromocytoma sites. Nucl Med Commun 2006;27:31-6 https://doi.org/10.1097/01.mnm.0000189780.54658.e8
  17. Park CK, Kim KW, Kim DH, Kim JH, Kang JG, Kim SW, et al. The efficacy of MIBG scan as a diagnostic and localization test for pheochromocytoma. J Kor Soc Endocrinol 2005;20:21-8 https://doi.org/10.3803/jkes.2005.20.1.21